263 related articles for article (PubMed ID: 36215167)
1. Neurological applications of belzutifan in von Hippel-Lindau disease.
Zhang Y; Nguyen CC; Zhang NT; Fink NS; John JD; Venkatesh OG; Roe JD; Hoffman SC; Lesniak MS; Wolinsky JP; Horbinski C; Szymaniak BM; Buerki RA; Sosman JA; Shenoy NK; Lukas RV
Neuro Oncol; 2023 May; 25(5):827-838. PubMed ID: 36215167
[TBL] [Abstract][Full Text] [Related]
2. The outcome of central nervous system hemangioblastomas in Von Hippel-Lindau (VHL) disease treated with belzutifan: a single-institution retrospective experience.
Zamarud A; Marianayagam NJ; Park DJ; Yener U; Yoo KH; Meola A; Chang SD
J Neurooncol; 2023 Nov; 165(2):373-379. PubMed ID: 37955759
[TBL] [Abstract][Full Text] [Related]
3. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
Jonasch E; Donskov F; Iliopoulos O; Rathmell WK; Narayan VK; Maughan BL; Oudard S; Else T; Maranchie JK; Welsh SJ; Thamake S; Park EK; Perini RF; Linehan WM; Srinivasan R;
N Engl J Med; 2021 Nov; 385(22):2036-2046. PubMed ID: 34818478
[TBL] [Abstract][Full Text] [Related]
4. Belzutifan in adults with VHL-associated central nervous system hemangioblastoma: a single-center experience.
Neth BJ; Webb MJ; White J; Uhm JH; Pichurin PN; Sener U
J Neurooncol; 2023 Aug; 164(1):239-247. PubMed ID: 37450072
[TBL] [Abstract][Full Text] [Related]
5. Belzutifan: A Narrative Drug Review.
Visweswaran V; Pavithran K
Curr Drug Res Rev; 2022; 14(2):88-95. PubMed ID: 35366789
[TBL] [Abstract][Full Text] [Related]
6. Belzutifan in a Patient With VHL-Associated Metastatic Pancreatic Neuroendocrine Tumor.
Pelle E; Al-Toubah T; Morse B; Strosberg J
J Natl Compr Canc Netw; 2022 Dec; 20(12):1285-1287. PubMed ID: 36509068
[TBL] [Abstract][Full Text] [Related]
7. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
8. Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation.
Chan KH; Li N; Lador R; Amsbaugh M; Gonzalez A; Cen P
J Investig Med High Impact Case Rep; 2024; 12():23247096241231641. PubMed ID: 38344974
[TBL] [Abstract][Full Text] [Related]
9. First clinical experience with belzutifan in von Hippel-Lindau disease associated CNS hemangioblastoma.
Dhawan A; Peereboom DM; Stevens GH
CNS Oncol; 2022 Jul; 11(3):CNS91. PubMed ID: 35819008
[TBL] [Abstract][Full Text] [Related]
10. Extraneuraxial hemangioblastoma: A clinicopathologic study of 10 cases with molecular analysis of the VHL gene.
Muscarella LA; Bisceglia M; Galliani CA; Zidar N; Ben-Dor DJ; Pasquinelli G; la Torre A; Sparaneo A; Fanburg-Smith JC; Lamovec J; Michal M; Bacchi CE
Pathol Res Pract; 2018 Aug; 214(8):1156-1165. PubMed ID: 29941223
[TBL] [Abstract][Full Text] [Related]
11. The road to systemic therapy in von Hippel-Lindau (VHL) disease: Are we there yet?
Shepherd STC; Drake WM; Turajlic S
Eur J Cancer; 2023 Mar; 182():15-22. PubMed ID: 36708612
[TBL] [Abstract][Full Text] [Related]
12. Intronic mutation of the VHL gene associated with central nervous system hemangioblastomas in two Chinese families with Von Hippel-Lindau disease: case report.
Liu Z; Zhou J; Li L; Yi Z; Lu R; Li C; Gong K
BMC Med Genet; 2020 Oct; 21(1):191. PubMed ID: 33004005
[TBL] [Abstract][Full Text] [Related]
13. Von Hippel-Lindau disease: a single gene, several hereditary tumors.
Crespigio J; Berbel LCL; Dias MA; Berbel RF; Pereira SS; Pignatelli D; Mazzuco TL
J Endocrinol Invest; 2018 Jan; 41(1):21-31. PubMed ID: 28589383
[TBL] [Abstract][Full Text] [Related]
14. Molecular pathology and CXCR4 expression in surgically excised retinal hemangioblastomas associated with von Hippel-Lindau disease.
Liang X; Shen D; Huang Y; Yin C; Bojanowski CM; Zhuang Z; Chan CC
Ophthalmology; 2007 Jan; 114(1):147-56. PubMed ID: 17070589
[TBL] [Abstract][Full Text] [Related]
15. von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance.
Louise M Binderup M; Smerdel M; Borgwadt L; Beck Nielsen SS; Madsen MG; Møller HU; Kiilgaard JF; Friis-Hansen L; Harbud V; Cortnum S; Owen H; Gimsing S; Friis Juhl HA; Munthe S; Geilswijk M; Rasmussen ÅK; Møldrup U; Graumann O; Donskov F; Grønbæk H; Stausbøl-Grøn B; Schaffalitzky de Muckadell O; Knigge U; Dam G; Wadt KA; Bøgeskov L; Bagi P; Lund L; Stochholm K; Ousager LB; Sunde L
Eur J Med Genet; 2022 Aug; 65(8):104538. PubMed ID: 35709961
[TBL] [Abstract][Full Text] [Related]
16. De novo VHL germline mutation detected in a patient with mild clinical phenotype of von Hippel-Lindau disease.
Ding X; Zhang C; Frerich JM; Germanwala A; Yang C; Lonser RR; Mao Y; Zhuang Z; Zhang M
J Neurosurg; 2014 Aug; 121(2):384-386. PubMed ID: 24678776
[TBL] [Abstract][Full Text] [Related]
17. Exceptional and Sustained Response to Belzutifan in Von Hippel-Lindau Disease-Associated Central Nervous System Hemangioblastoma.
Thalji M; Vadlapatla V; Avgeropoulos NG; Ramakrishna N; Baidas S
Cureus; 2024 Jan; 16(1):e52979. PubMed ID: 38406059
[TBL] [Abstract][Full Text] [Related]
18. A Case of von Hippel-Lindau Disease with Colorectal Adenocarcinoma, Renal Cell Carcinoma and Hemangioblastomas.
Heo SJ; Lee CK; Hahn KY; Kim G; Hur H; Choi SH; Han KS; Cho A; Jung M
Cancer Res Treat; 2016 Jan; 48(1):409-14. PubMed ID: 25715769
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive characterization of a Canadian cohort of von Hippel-Lindau disease patients.
Salama Y; Albanyan S; Szybowska M; Bullivant G; Gallinger B; Giles RH; Asa S; Badduke C; Chiorean A; Druker H; Ezzat S; Hannah-Shmouni F; Hernandez KG; Inglese C; Jani P; Kaur Y; Krema H; Krimus L; Laperriere N; Lichner Z; Mete O; Sit M; Zadeh G; Jewett MAS; Malkin D; Stockley T; Wasserman JD; Xu W; Schachter NF; Kim RH
Clin Genet; 2019 Nov; 96(5):461-467. PubMed ID: 31368132
[TBL] [Abstract][Full Text] [Related]
20. FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors.
Fallah J; Brave MH; Weinstock C; Mehta GU; Bradford D; Gittleman H; Bloomquist EW; Charlab R; Hamed SS; Miller CP; Dorff SE; Chambers WA; Mixter BD; Dinin J; Pierce WF; Ricks TK; Tang S; Donoghue M; Pazdur R; Amiri-Kordestani L; Ibrahim A; Beaver JA
Clin Cancer Res; 2022 Nov; 28(22):4843-4848. PubMed ID: 35727604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
